ALGN vs PTGX
Align Technology vs Protagonist Therapeutics, Inc. — AI-powered side-by-side comparison
ALGN
Align Technology
73
Buy
VS
PTGX
Protagonist Therapeutics, Inc.
65
Buy
| Metric | ALGN | PTGX |
|---|
| AI Score |
73
|
65
|
| Price |
$172.86
|
$148.25
|
| P/E Ratio |
30.03×
|
121.74×
|
| ROE |
10.1%
|
-21.2%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
66.5%
|
99.9%
|
| Debt / Equity |
0.03×
|
0.01×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
55.1
|
68.1
|
| Beta |
1.653
|
1.794
|
| Expected Upside |
+7.7%
|
—
|
AI Committee View
Current Innellis committee reasoning for ALGN versus PTGX.
ALGN leads by 8 points.
ALGN scores 73/100 (Buy) versus PTGX at 65/100 (Buy).
ALGN Committee View
100% agreement
5 analysts
The primary driver is quarter-over-quarter growth rate is accelerating, not just positive. The main limiting factor is 2 existing position pair(s) are highly correlated already. The committee is constructive but not yet at full conviction.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- MACD histogram positive -- bullish momentum — Technical
- Weekly trend (sideways) confirms the daily trend -- multi-timeframe agreement — Technical
Bear Case
- Both daily and weekly trends are bearish — strong multi-timeframe downtrend.
PTGX Committee View
67% agreement
6 analysts
The committee is genuinely divided. Growth Analyst sees a compelling case — revenue growing 34.8% yoy -- genuine top-line momentum. Value Analyst remains cautious — p/e of 115.4 is expensive by classic value standards. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- Revenue growing 34.8% YoY -- genuine top-line momentum — Growth
- EPS growing 46.0% YoY — Growth
- Price structure making higher highs and higher lows — Technical
Bear Case
- P/E of 115.4 is expensive by classic value standards — Value
- Price-to-book of 8.9x prices in significant intangible value — Value
- Weekly RSI at 84 -- overbought on the larger timeframe too — Technical